RS75303A - N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad - Google Patents

N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad

Info

Publication number: RS75303A
Authority: RS; Serbia
Prior art keywords: optionally substituted; phenpropylcyclopentyl; fsad; substituted; nep inhibitors
Prior art date: 2001-03-28

Application number

YU75303A

Other languages

English (en)

Serbian (sr)

Inventor

Stephen Challenger

Andrew Simon Cook

Adam Thomas Gillmore

Donald Stuart Middleton

David Cameron Pryde

Alan Stobie

Original Assignee

Pfizer Limited

Pfizer Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-28

Filing date

2002-03-18

Publication date

2006-12-15

2001-03-28 Priority claimed from GB0107750A external-priority patent/GB0107750D0/en

2001-05-30 Priority claimed from GB0113112A external-priority patent/GB0113112D0/en

2001-08-17 Priority claimed from GB0120152A external-priority patent/GB0120152D0/en

2002-03-18 Application filed by Pfizer Limited, Pfizer Inc. filed Critical Pfizer Limited

2006-12-15 Publication of RS75303A publication Critical patent/RS75303A/sr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/82—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/40—Y being a hydrogen or a carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Gynecology & Obstetrics (AREA)
Urology & Nephrology (AREA)
Dispersion Chemistry (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Pyrane Compounds (AREA)
Quinoline Compounds (AREA)
Furan Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

YU75303A 2001-03-28 2002-03-18 N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad RS75303A (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB0107750A GB0107750D0 (en)	2001-03-28	2001-03-28	Novel pharmaceuticals
GB0113112A GB0113112D0 (en)	2001-05-30	2001-05-30	Novel pharmaceuticals
GB0120152A GB0120152D0 (en)	2001-08-17	2001-08-17	Novel pharmaceuticals
PCT/IB2002/000807 WO2002079143A1 (en)	2001-03-28	2002-03-18	N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad

Publications (1)

Publication Number	Publication Date
RS75303A true RS75303A (en)	2006-12-15

Family

ID=27256128

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
YU75303A RS75303A (en)	2001-03-28	2002-03-18	N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad

Country Status (34)

Country	Link
EP (1)	EP1373192A1 (pt)
JP (1)	JP4018545B2 (pt)
KR (1)	KR100564466B1 (pt)
CN (1)	CN1243723C (pt)
AP (1)	AP1689A (pt)
AR (1)	AR035795A1 (pt)
BG (1)	BG108130A (pt)
BR (1)	BR0208455A (pt)
CA (1)	CA2437113A1 (pt)
CZ (1)	CZ20032534A3 (pt)
DO (1)	DOP2002000364A (pt)
EA (1)	EA006154B1 (pt)
EE (1)	EE200300469A (pt)
GE (1)	GEP20063783B (pt)
HK (1)	HK1060724A1 (pt)
HR (1)	HRP20030751A2 (pt)
HU (1)	HUP0303624A3 (pt)
IL (1)	IL157009A0 (pt)
IS (1)	IS6877A (pt)
MA (1)	MA26996A1 (pt)
MX (1)	MXPA03006597A (pt)
MY (1)	MY134081A (pt)
NO (1)	NO20034299L (pt)
NZ (1)	NZ527012A (pt)
OA (1)	OA12553A (pt)
PA (1)	PA8542401A1 (pt)
PE (1)	PE20021014A1 (pt)
PL (1)	PL365101A1 (pt)
RS (1)	RS75303A (pt)
SK (1)	SK11822003A3 (pt)
TN (1)	TNSN02032A1 (pt)
TW (1)	TWI254038B (pt)
UY (1)	UY27227A1 (pt)
WO (1)	WO2002079143A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040014761A1 (en) *	1997-10-28	2004-01-22	Place Virgil A.	Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US7183410B2 (en)	2001-08-02	2007-02-27	Bidachem S.P.A.	Stable polymorph of flibanserin
UA78974C2 (en)	2001-10-20	2007-05-10	Boehringer Ingelheim Pharma	Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en)	2001-10-20	2020-06-09	Sprout Pharmaceuticals, Inc.	Treating sexual desire disorders with flibanserin
JP2005512995A (ja) *	2001-11-09	2005-05-12	ファイザーヘルスアーベー	不安定又は過活動膀胱を治療するための抗ムスカリン剤及びエストロゲンアゴニスト
GB0130219D0 (en) *	2001-12-18	2002-02-06	Pfizer Ltd	Compounds for the treatment of sexual dysfunction
GB0230036D0 (en) *	2002-12-23	2003-01-29	Pfizer Ltd	Novel pharmaceuticals
GB0230025D0 (en) *	2002-12-23	2003-01-29	Pfizer Ltd	Novel pharmaceuticals
PA8597401A1 (es) *	2003-03-14	2005-05-24	Pfizer	Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
US7452875B2 (en)	2003-09-26	2008-11-18	Solvay Pharmaceuticals Gmbh	Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7262184B2 (en)	2003-09-26	2007-08-28	Solvay Pharmaceuticals Gmbh	Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7427611B2 (en)	2003-09-26	2008-09-23	Solvay Pharmaceuticals Gmbh	Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7649002B2 (en)	2004-02-04	2010-01-19	Pfizer Inc	(3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
CA2566699C (en)	2004-05-11	2016-02-16	Emotional Brain B.V.	Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
US20060025420A1 (en) *	2004-07-30	2006-02-02	Boehringer Ingelheimn International GmbH	Pharmaceutical compositions for the treatment of female sexual disorders
WO2006027680A1 (en) *	2004-09-10	2006-03-16	Pfizer Limited	3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme
JP2009503020A (ja)	2005-08-03	2009-01-29	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	肥満症の治療におけるフリバンセリンの使用
CA2626134C (en)	2005-10-29	2013-12-24	Boehringer Ingelheim International Gmbh	Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
EP1790343A1 (en) *	2005-11-11	2007-05-30	Emotional Brain B.V.	Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP2037927B1 (en)	2006-06-30	2010-01-27	Boehringer Ingelheim International GmbH	Flibanserin for the treatment of urinary incontinence and related diseases
CA2660476C (en)	2006-08-14	2015-11-17	Boehringer Ingelheim International Gmbh	Formulations of flibanserin and method for manufacturing the same
MX2009002031A (es)	2006-08-25	2009-03-06	Boehringer Ingelheim Int	Sistema de liberacion controlada y metodo para fabricarlo.
WO2008057857A1 (en) *	2006-11-01	2008-05-15	Bristol-Myers Squibb Company	MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
EP1925307A1 (en)	2006-11-03	2008-05-28	Emotional Brain B.V.	Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
PE20091188A1 (es)	2007-09-12	2009-08-31	Boehringer Ingelheim Int	Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
US8993631B2 (en)	2010-11-16	2015-03-31	Novartis Ag	Method of treating contrast-induced nephropathy
US8877815B2 (en) *	2010-11-16	2014-11-04	Novartis Ag	Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
EP3082428A4 (en)	2013-12-09	2017-08-02	Respira Therapeutics, Inc.	Pde5 inhibitor powder formulations and methods relating thereto
SI3303330T1 (sl)	2015-06-03	2019-08-30	Bristol-Myers Squibb Company	Agonisti 4-hidroksi-3-(heteroaril)piridin-2-on apj za uporabo pri zdravljenju kardiovaskularnih motenj
EP3554507A1 (en)	2016-12-14	2019-10-23	Respira Therapeutics, Inc.	Methods and compositions for treatment of pulmonary hypertension and other lung disorders
CN107746400A (zh) *	2017-12-04	2018-03-02	武汉药明康德新药开发有限公司	苯并二氢吡喃‑6‑磺酰氯的制备方法
TW202413336A (zh)	2018-03-08	2024-04-01	美商英塞特公司	作為PI3K-γ抑制劑之胺基吡嗪二醇化合物
US11046658B2 (en)	2018-07-02	2021-06-29	Incyte Corporation	Aminopyrazine derivatives as PI3K-γ inhibitors
CN110483403A (zh) *	2019-09-02	2019-11-22	南通大学	一种5-溴-4-甲氧基-1h-吲唑的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2069112A1 (en)	1989-11-21	1991-05-22	Bernard R. Neustadt	Carboxyalkylcarbonyl aminoacid endopeptidase inhibitors
GB9000725D0 (en)	1990-01-12	1990-03-14	Pfizer Ltd	Therapeutic agents
GB9004260D0 (en)	1990-02-26	1990-04-18	Pfizer Ltd	Therapeutic agents
US5208236A (en) *	1992-09-23	1993-05-04	Schering Corporation	N-(acylaminomethyl)glutaryl amino acids and use
IL139454A0 (en)	1999-11-08	2001-11-25	Pfizer	Compounds for the treatment of female sexual dysfunction
US20020052370A1 (en) *	2000-07-06	2002-05-02	Barber Christopher Gordon	Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase

2002
- 2002-03-18 CN CNB028054091A patent/CN1243723C/zh not_active Expired - Fee Related
- 2002-03-18 JP JP2002577770A patent/JP4018545B2/ja not_active Expired - Fee Related
- 2002-03-18 IL IL15700902A patent/IL157009A0/xx unknown
- 2002-03-18 SK SK1182-2003A patent/SK11822003A3/sk unknown
- 2002-03-18 GE GE5313A patent/GEP20063783B/en unknown
- 2002-03-18 EE EEP200300469A patent/EE200300469A/xx unknown
- 2002-03-18 NZ NZ527012A patent/NZ527012A/en unknown
- 2002-03-18 CA CA002437113A patent/CA2437113A1/en not_active Abandoned
- 2002-03-18 RS YU75303A patent/RS75303A/sr unknown
- 2002-03-18 EA EA200300777A patent/EA006154B1/ru unknown
- 2002-03-18 WO PCT/IB2002/000807 patent/WO2002079143A1/en active IP Right Grant
- 2002-03-18 KR KR1020037012690A patent/KR100564466B1/ko not_active IP Right Cessation
- 2002-03-18 EP EP02707042A patent/EP1373192A1/en not_active Withdrawn
- 2002-03-18 DO DO2002000364A patent/DOP2002000364A/es unknown
- 2002-03-18 BR BR0208455-4A patent/BR0208455A/pt not_active IP Right Cessation
- 2002-03-18 PL PL02365101A patent/PL365101A1/xx not_active Application Discontinuation
- 2002-03-18 CZ CZ20032534A patent/CZ20032534A3/cs unknown
- 2002-03-18 OA OA1200300204A patent/OA12553A/en unknown
- 2002-03-18 MX MXPA03006597A patent/MXPA03006597A/es active IP Right Grant
- 2002-03-18 HU HU0303624A patent/HUP0303624A3/hu unknown
- 2002-03-22 TW TW091105650A patent/TWI254038B/zh not_active IP Right Cessation
- 2002-03-25 UY UY27227A patent/UY27227A1/es not_active Application Discontinuation
- 2002-03-26 MY MYPI20021077A patent/MY134081A/en unknown
- 2002-03-26 AR ARP020101114A patent/AR035795A1/es unknown
- 2002-03-26 PE PE2002000240A patent/PE20021014A1/es not_active Application Discontinuation
- 2002-03-27 TN TNTNSN02032A patent/TNSN02032A1/fr unknown
- 2002-03-27 PA PA20028542401A patent/PA8542401A1/es unknown
- 2002-03-28 AP APAP/P/2002/002467A patent/AP1689A/en active
2003
- 2003-07-17 IS IS6877A patent/IS6877A/is unknown
- 2003-08-13 MA MA27280A patent/MA26996A1/fr unknown
- 2003-08-25 BG BG108130A patent/BG108130A/bg unknown
- 2003-09-17 HR HR20030751A patent/HRP20030751A2/xx not_active Application Discontinuation
- 2003-09-26 NO NO20034299A patent/NO20034299L/no not_active Application Discontinuation
2004
- 2004-05-25 HK HK04103713A patent/HK1060724A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
KR100564466B1 (ko)	2006-03-29
BG108130A (bg)	2004-07-30
OA12553A (en)	2006-06-07
CN1243723C (zh)	2006-03-01
WO2002079143A1 (en)	2002-10-10
EA006154B1 (ru)	2005-10-27
HK1060724A1 (en)	2004-08-20
UY27227A1 (es)	2002-10-31
AP2002002467A0 (en)	2002-06-30
BR0208455A (pt)	2004-03-02
SK11822003A3 (sk)	2004-09-08
AP1689A (en)	2006-12-07
GEP20063783B (en)	2006-04-10
CA2437113A1 (en)	2002-10-10
PE20021014A1 (es)	2002-11-12
HUP0303624A2 (hu)	2004-03-01
HRP20030751A2 (en)	2005-08-31
CZ20032534A3 (cs)	2004-07-14
IL157009A0 (en)	2004-02-08
MY134081A (en)	2007-11-30
TNSN02032A1 (fr)	2005-12-23
JP2004531505A (ja)	2004-10-14
PA8542401A1 (es)	2002-10-28
MXPA03006597A (es)	2004-10-15
NZ527012A (en)	2005-03-24
JP4018545B2 (ja)	2007-12-05
KR20030092032A (ko)	2003-12-03
PL365101A1 (en)	2004-12-27
HUP0303624A3 (en)	2005-06-28
DOP2002000364A (es)	2002-10-15
EA200300777A1 (ru)	2003-12-25
TWI254038B (en)	2006-05-01
AR035795A1 (es)	2004-07-14
EP1373192A1 (en)	2004-01-02
NO20034299D0 (no)	2003-09-26
MA26996A1 (fr)	2004-12-20
IS6877A (is)	2003-07-17
NO20034299L (no)	2003-11-27
CN1492852A (zh)	2004-04-28
EE200300469A (et)	2004-02-16

Publication	Publication Date	Title
RS75303A (en)	2006-12-15	N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad
CY1113209T1 (el)	2016-04-13	Νεα παραγωγα πυρρολο [3,2-d] πυριμιδιν-4-ονης και η χρηση τους στη θεραπεια
CY1107196T1 (el)	2012-11-21	Υποκατεστημενα παραγωγα 2,4-διϋδρο-πυρρολο (3,4-β) -κινολιν-9-ονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
PE20061417A1 (es)	2007-01-20	Metodo para sintetizar 3-cianoquinolinas sustituidas y sus intermediarios
EA200401157A1 (ru)	2005-06-30	N-аминоацетилпирролидин-2-карбонитрилы и их применение в качестве ингибиторов ddp-iv
AR013184A1 (es)	2000-12-13	Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
DK0626853T3 (da)	2000-08-07	Anvendelse af substituerede adeninderivater til behandling af multipel sclerose
CY1107532T1 (el)	2013-03-13	Παραγωγα ναφθυριδινης, παρασκευη και χρηση τους ως αναστολεις του ισοενζυμου 4 της φωσφοδιεστepασης (pde4)
UA39099C2 (uk)	2001-06-15	Циклічні азотовмісні похідні, суміш їх ізомерів або окремі ізомери, або їх солі
CY1107793T1 (el)	2013-06-19	Εκκριματαγωγa αυξητικhς ορμoνης
MY119542A (en)	2005-06-30	Therapeutic biaryl derivatives
EA200401160A1 (ru)	2005-02-24	Производные тиазола и оксазола, которые модулируют активность ppar
CY1114240T1 (el)	2016-08-31	Παραγωγα σουλφοναμιδιου τετραϋδροϊσοκινολινης, η παρασκευη τους και η χρηση τους στη θεραπευτικη
DK0700380T3 (da)	1998-11-09	N-Alkylthiopolyaminderivater som radioprotektive midler
DK0503453T3 (da)	2001-07-16	Fremgangsmåde til fremstilling af cephalosporiner og mellemprodukter i denne fremgangsmåde
PL341539A1 (en)	2001-04-23	Heterocyclic toxins of topoisomerases
UY27413A1 (es)	2003-02-28	Agonistas de la oxitocina
EP1473295A4 (en)	2005-12-28	BICYCLIC FUSIONED PYRIMIDINE DERIVATIVES
ES2157899T3 (es)	2001-09-01	Derivados de sampangina utiles como agentes antifungicos y antimicobacterianos.
PT95369A (pt)	1991-05-22	Processo para a preparacao de novos benzopiranona-beta-d-tioxilosidos uteis em terapeutica
KR950700684A (ko)	1995-02-20	시클릭 항-종양 촉진제 화합물, 그의 조성물, 제조 방법 및 용도(Cyclic Anti-Tumor Promoter Compounds, Compositions and Methods for Production and Use)
EA200400822A1 (ru)	2004-12-30	Производные 3,4-дигидро-1h-изохинолин-2-ила
HUP0000233A2 (hu)	2001-04-28	Pirazolinon-származékok alkalmazása potenciazavarok kezelésére szolgáló gyógyszerkészítmények előállítására
MXPA01013148A (es)	2004-08-19	Nuevos derivados de amonio cuaternario, metodo para la preparacion de los mismos y uso farmaceutico.
CY1107287T1 (el)	2012-11-21	Χρηση της ερυθροποιητινης, καθως και παραγωγων αυτης για τη θεραπεια σχιζοφρενειων και συναφων ψυχωσεων